Drugs / Atenolol
Atenolol
also known as
ATE · Tenormin · Antipressan · Atenamin · Atenix-100 · Atenix-25 · Atenix-50 · Atenolol component of polycap · +22 more
Other / unclassified targets ADRB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | TENORMIN | — | 1985-09-04 – 1990-04-09 | fda.gov ↗ |
| Approved | US (FDA) | TENORMIN | — | 1981-08-19 | fda.gov ↗ |
Trials 61 · started per year
today
US approved 1981
2
1
1
1
1
1
4
2
3
5
5
3
2
2
1
4
5
1
1
3
1
2
2
2
2
2
1
1
198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03147092 | Feb 2018 → Jun 2020 | hypertensive disorder | Centro Neurológico de Pesquisa e Reabiitação, Brazil | Unknown | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT02479204 | Apr 2015 → May 2016 | — | Viatris Innovation GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT02262533 | Jun 2007 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00310778 | Mar 2006 → Mar 2007 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT00158093 | Jun → Jul 2003 | essential hypertension | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00913965 | Jul → Aug 1989 | hypertensive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03361280 | Feb 2015 → Mar 2016 | chronic kidney disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 1/2 | NCT03070730 | Aug 2011 → Dec 2012 | postural orthostatic tachycardia syndrome | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04905277 | Jul 2021 → Feb 2026 | — | Sundeep Khosla, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT03329599 | Feb 2019 → Dec 2021 | atherosclerosis | Northern California Institute of Research and Education | Completed | Missed primary |
| Phase 2 | NCT03578354 | Jan 2019 → Jan 2023 | migraine disorder, vestibular disorder | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00200421 | May 2002 → Aug 2003 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07268170 | Dec 2025 → Sep 2028 expected | coronary artery disorder, ischemic disease | Gødstrup Hospital | Enrolling by invitation | No outcome recorded |
| Phase 316 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT05963568 | Apr 2026 → Jan 2029 expected | stroke disorder | Northern California Institute of Research and Education | Recruiting | No outcome recorded |
| Phase 3 | NCT03237637 | Mar 2017 → Dec 2018 | hemangioma | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT01313702 | Oct 2012 → Apr 2014 | cardiovascular disorder | Hospital do Coracao | Withdrawn | No outcome recorded |
| Phase 3 | NCT01646437 | Jun 2012 → Jun 2020 | cardiovascular disorder | Population Health Research Institute | Completed | Mixed |
| Phase 3 | NCT01202721 | Jun 2011 → Apr 2016 | heart disorder | Hamilton Health Sciences Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01326676 | Feb 2011 → Jul 2012 | cardiovascular disorder | Imperial College London | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01057537 | Jun 2010 → Jul 2012 | cardiovascular disorder | Imperial College London | Completed | Met primary |
| Phase 3 | NCT01145612 | Oct 2008 → Feb 2013 | Marfan syndrome | Forteza, Albert, M.D. | Unknown | No outcome recorded |
| Phase 3 | NCT00396656 | Dec 2005 → Dec 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00145210 | Apr 2005 → Sep 2007 | hypertensive disorder | Mylan Bertek Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00108082 | Jan 2005 → Aug 2008 | heart disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00541684 | Jul 2001 → Jan 2003 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00338260 | Jun 1995 → Sep 2001 | hypertensive heart disease | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00000478 | Nov 1990 → Jun 1997 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000514 | Jun 1984 → Oct 1996 | cerebrovascular disorder, heart disorder, hypertensive disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000513 | Apr 1984 → Nov 1994 | heart disorder, hypertensive disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 421 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04931108 | Sep 2021 → Jun 2023 | essential hypertension | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03596385 | Oct 2018 → Jan 2025 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | Missed primary |
| Phase 4 | NCT03245996 | Jun 2015 → Sep 2016 | — | Tartu University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01904981 | Jan 2014 → Apr 2017 | abdominal aortic aneurysm | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01939509 | Feb 2012 → Oct 2014 | hypertensive disorder, metabolic syndrome X | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 4 | NCT01445964 | May → Nov 2011 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00925119 | Dec 2009 → Jun 2013 | type 2 diabetes mellitus | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 4 | NCT00669279 | Apr 2008 → Jul 2010 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT01030016 | May 2007 → May 2009 | hypertensive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00241904 | May 2006 → May 2010 | atherosclerosis, coronary artery disorder, diabetes mellitus, hypertensive disorder +1 | Johns Hopkins University | Completed | Mixed |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00246519 | Oct 2005 → Dec 2010 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00171132 | Aug 2004 → Aug 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00171756 | Jun 2004 → Mar 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00185094 | Feb 2004 → Jul 2005 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00140959 | Feb 2003 → Jun 2004 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00202358 | Nov 2002 → Nov 2007 | — | Saini Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT00507663 | Sep 2002 → Nov 2007 | subjective cognitive decline | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT00133692 | Sep 1997 → Feb 2003 | coronary artery disorder, hypertensive disorder | University of Florida | Completed | Met primary |
| Phase not applicable11 trials · 1 met primary · 1 missed | ||||||
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04224675 | Mar 2020 → Mar 2023 | aneurysm or dilatation of ascending aorta | Onassis Cardiac Surgery Centre | Unknown | No outcome recorded |
| — | NCT01719367 | Jan 2013 → Sep 2016 | persistent atrial fibrillation | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01795235 | Dec 2012 → Jul 2014 | — | University of Virginia | Unknown | No outcome recorded |
| — | NCT01839253 | Aug 2012 → Mar 2014 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT00837902 | Jan 2009 → Dec 2012 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01009944 | Jan 2007 → Mar 2019 | hypertensive disorder | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Business |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00380289 | Sep 2006 → ? | essential hypertension | University of Cambridge | Unknown | Met primary |
| — | NCT00125853 | Jul 2006 → Jan 2009 | hypertensive disorder | Imperial College London | Completed | Missed primary |
| — | NCT00151138 | Sep 2002 → May 2007 | hypertensive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Comparator or background therapy56 trials | ||||||
| Phase 0 | NCT03245970 Comparator | Apr 2017 → Feb 2020 | preeclampsia | University of Tennessee Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03105661 Comparator | Apr 2017 → Dec 2019 | morbid obesity, preeclampsia | University of Tennessee Graduate School of Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT02467400 Comparator | Jul 2015 → Oct 2017 | postmenopausal osteoporosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00946725 Comparator | Nov 2000 | hypertensive disorder, intermediate coronary syndrome | Sandoz | Completed | No outcome recorded |
| Phase 2 | NCT04320589 Comparator | Jun 2019 → Aug 2021 | pheochromocytoma | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2 | NCT02560805 Comparator | Oct 2015 → Mar 2027 expected | post-traumatic stress disorder | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT02623569 Comparator | Oct 2014 → Jun 2017 | coronary artery disorder | Xintong Pharmacy Company | Unknown | No outcome recorded |
| Phase 2 | NCT01522950 Comparator | May 2010 → Oct 2016 | hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00593710 Comparator | Jan 2008 → Oct 2010 | Marfan syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00651235 Comparator | Feb 2007 → Feb 2011 | Marfan syndrome | National Taiwan University Hospital | Unknown | Met primary |
| Phase 2/3 | NCT00389168 Comparator | Apr 1995 → Apr 1997 | hypertensive disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT03082014 Comparator | Feb 2018 → Jul 2022 | cerebrovascular disorder | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02342275 Comparator | Oct 2013 → Sep 2018 | hemangioma | West China Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01715207 Background | Jun 2010 → Oct 2014 | Marfan syndrome | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01022463 Comparator | Nov 2009 → Oct 2010 | mitral valve stenosis | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00589303 Comparator | Dec 2007 → Jul 2011 | atrial fibrillation, heart failure | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00723801 Comparator | Oct 2007 → Dec 2012 | Marfan syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00429364 Comparator | Jan 2007 → Feb 2014 | Marfan syndrome | Carelon Research | Completed | No outcome recorded |
| Phase 3 | NCT00582114 Comparator | Aug 2005 → Sep 2013 | essential hypertension, heart disorder | Indiana University | Terminated | Missed primary |
| Phase 3 | NCT00185185 Comparator | Nov 2001 → Feb 2006 | atherosclerotic cardiovascular disease, essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 4 | NCT07298993 Comparator | Feb 2026 → Apr 2029 expected | heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04914234 Comparator | Dec 2025 → Jan 2027 expected | hypotensive disorder | Damanhour Teaching Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05106179 Comparator | Dec 2021 → Dec 2022 | hemangioma, poisoning, spinal cord neoplasm | Center for Vascular Pathology, Moscow | Unknown | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT07405229 Comparator | May 2018 → Dec 2032 expected | cardiac arrest, ventricular fibrillation | Bo Gregers Winkel | Recruiting | No outcome recorded |
| Phase 4 | NCT01736488 Comparator | Oct 2012 → Jun 2016 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02403349 Comparator | May 2012 → May 2015 | hypertensive disorder, ischemic stroke | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01397994 Comparator | Sep 2011 → Jan 2012 | intermediate coronary syndrome | Ferozsons Laboratories Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02547597 Comparator | Apr 2011 → Aug 2013 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01762436 Comparator | Nov 2010 → Feb 2012 | essential hypertension | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01251146 Comparator | Nov 2010 → Feb 2012 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01132768 Comparator | May 2010 → Jun 2011 | carotid artery disorder, essential hypertension | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01230892 Comparator | Feb 2010 → Sep 2013 | atherosclerosis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01070030 Background | Jan → Oct 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01079962 Comparator | Dec 2009 → Oct 2011 | hypertensive disorder | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 4 | NCT00438113 Comparator | Dec 2009 → Sep 2016 | atrial fibrillation | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00687973 Comparator | Jan 2008 → Jan 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01295047 Comparator | Jul 2006 → Dec 2007 | Marfan syndrome | Cardiff University | Completed | No outcome recorded |
| Phase 4 | NCT02441842 Comparator | Mar 2006 → Dec 2008 | malignant secondary hypertension | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00263393 Background | Dec 2005 → Dec 2008 | coronary artery disorder, diabetes mellitus, myocardial infarction, stroke disorder | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT00661895 Background | Aug 2005 → Aug 2009 | hypertensive disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00232882 Comparator | Dec 2003 → Apr 2006 | essential hypertension | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00772499 Comparator | Nov 2002 → Jul 2005 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 4 | NCT00529750 Comparator | Jul 2002 → Jan 2005 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00813722 Comparator | Mar 1999 → Jan 2009 | hypertensive disorder | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT07445334 Comparator | Mar 2026 → Sep 2027 expected | ventricular tachycardia | Western Sydney Local Health District | Recruiting | No outcome recorded |
| — | NCT06670690 Comparator | Sep 2023 | — | Menoufia University | Completed | No outcome recorded |
| — | NCT06505668 Comparator | Aug 2023 → Jun 2025 overdue | cardiac rhythm disease, treatment-refractory schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Recruiting | No outcome recorded |
| — | NCT01117454 Background | Dec 2011 → Dec 2015 | catecholaminergic polymorphic ventricular tachycardia | Vanderbilt University Medical Center | Completed | Met primary |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00625742 Background | Feb 2008 → Jun 2014 | cancer of unknown primary site, hypoproteinemia, hypercatabolic | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00443794 Comparator | Mar 2007 → Oct 2008 | cardiovascular disorder | St. John's Research Institute | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-06-18 | Daiichi Sankyo | Results New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering daiichisankyo.com ↗
This protective effect was not seen with the comparator agent in the study, atenolol. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-06-18 | Daiichi Sankyo | New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering daiichisankyo.com ↗ |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 119 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atenolol | “Other names:
acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗116“Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.” NCT07405229 ↗ “The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal.” NCT01070030 ↗ “A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol.” NCT05963568 ↗ “polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily” PMID 33186492 ↗ Nov 2020 “A capsule of Polycap contained aspirin 100 mg, simvastatin 20 mg, hydrochlorothiazide 12.5 mg, ramipril 5 mg, and atenolol 50 mg.” PMID 39082406 ↗ Jul 2024 “either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily” NCT00380289 ↗ “If sotalol is contraindicated, an alternative BB may be initiated using standard doses (metoprolol, atenolol, bisoprolol).” NCT07445334 ↗ |
| Known as | Antipressan | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | ATE | “Nebivolol (NEB) in contrast to atenolol (ATE) may have a beneficial effect on endothelial function and may be more effective than ATE in preventing CVD.” PMID 29184167 ↗ Nov 20171“Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily” NCT01132768 ↗ |
| Known as | Atenamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenix-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenix-25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenix-50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenolol component of polycap | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenolol component of tenoretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Atenolol/Atenorm | “Atenolol/Atenorm” NCT01397994 ↗ |
| Known as | Atenololum | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Betacard | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | C07AB03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Corotenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Duraatenolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Ibinolo | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | ICI 66,082 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Juvental | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Kentol | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Myocord | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Novaten | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | NSC-757832 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Prenormine | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Tenormin | “Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)” NCT00946725 ↗1“Atenolol (Tenormin): 25-100 mg/day” NCT04320589 ↗ |
| Known as | Tenormin (Atenolol) | “Tenormin (Atenolol)” NCT01009944 ↗ |
| Known as | Tenormin 25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Tenormin l.s. | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Totamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Unibloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Urosin | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Known as | Vasaten | ChEMBL registry synonym — accepted as the source's own label CHEMBL24 ↗ |
| Action | Inhibit | “uses a beta-blocker (atenolol) followed by addition of low-dose diuretic” NCT00133692 ↗1“Beta-1 adrenergic receptor antagonist” CHEMBL24 ↗ |
| Modality | Other / unclassified | “cardio selective beta blocker atenolol” NCT03237637 ↗ |
| Route | Oral | “a single oral dose of RAS blocking drugs (ramipril 10 mg, valsartan 160 mg, candesartan 8 mg) or a blocker as control (ATENOLOL 50 mg)” NCT00310778 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL24 ↗ |